EPV 001
Alternative Names: EPV-001Latest Information Update: 09 Oct 2022
Price :
$50 *
At a glance
- Originator University of Pennsylvania
- Developer EpiVario
- Class Anxiolytics; Drug withdrawal therapies; Small molecules
- Mechanism of Action Acetate-CoA ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alcoholism; Post-traumatic stress disorders; Substance-related disorders
Most Recent Events
- 22 Sep 2022 Preclinical trials in Alcoholism in USA (unspecified route) (EpiVario pipeline, September 2022)
- 22 Sep 2022 Preclinical trials in Post-traumatic stress disorders in USA (unspecified route) (EpiVario pipeline, September 2022)
- 22 Sep 2022 Preclinical trials in Substance-related disorders in USA (unspecified route) (EpiVario pipeline, September 2022)